Aytu BioPharma, Inc. (AYTU) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Please note this conference is being recorded. I will now turn the conference over to your host, Robert Bloom, Investor Relations at A2. Robert, you may begin. Thank you very much and good afternoon, everyone. As the operator indicated during today's call, we will be discussing A2 Biopharma's fiscal 2025 third quarter operational and financial results for the period ended March 31, 2025. With us on today's call is A2's Chief Executive Officer, Josh Dizbro, and Ryan Selhorn, the company's Chief Financial Officer. At the conclusion of today's prepared remarks, we'll open the call for a question and answer session. I'd like to remind everyone that today's call is being recorded. A replay of today's call will be available by using the teleconference numbers and conference ID provided in the press release issued earlier today, or by utilizing the link on the company's website under events and presentations. Finally, I'd also like to call to your attention the customary safe hardware disclosure regarding forward-looking information. The conference call today will contain certain forward-looking statements, including statements regarding the goals, strategies, beliefs, expectations, and future potential operating results of A2 Biopharma. Although the management believes these statements are reasonable based on estimates, assumptions, and projections as of today, these statements are not guarantees of future performance. Time-sensitive information may no longer be accurate at the time of any telephonic or webcast replay. Actual results may differ materially as a result of various risks, uncertainties, and other factors, including, but not limited to, the factors set forth in the company's filings with the SEC. A2 undertakes no obligation to update or revise any of these forw...